Skip to main content
Premium Trial:

Request an Annual Quote

Complete Genomics to Offer Ingenuity Variant Analysis with Whole-Genome Sequencing Service

Premium

Complete Genomics said this week that it will offer customers of its research whole-genome sequencing service access to Ingenuity's variant analysis capabilities.

Complete Genomics said that all orders for new research genomes will now include access to Ingenuity Variant Analysis for six months. The bundled offering will provide customers with a complete workflow to analyze, interpret, and prioritize biologically relevant genetic variations, the company said.

Ingenuity Variant Analysis, launched earlier this year, uses Ingenuity's database of curated biological data and mutation information to help researchers filter millions of variants in sequencing data sets to identify causal variants based on known relationships with pathways, genes, biological processes, and diseases (BI 1/13/2012).

As part of the agreement, customers who use Ingenuity Variant Analysis will receive access to a control dataset from the Wellderly study — a collaborative project between Complete Genomics and the Scripps Health System (BI 11/7/2011).

Financial details of this agreement were not disclosed.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.